iguratimod has been researched along with Rheumatoid Arthritis in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.45) | 18.2507 |
| 2000's | 7 (10.14) | 29.6817 |
| 2010's | 33 (47.83) | 24.3611 |
| 2020's | 28 (40.58) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, RR; Wu, F; Wu, TJ; Ying, ZH; Yu, JJ; Zhang, Y | 1 |
| Dan, J; Liu, Y; Tan, J | 1 |
| Fukuda, K; Funahashi, K; Hayashi, S; Itami, T; Kinoshita, K; Kuroda, R; Maeda, T; Matsubara, T; Matsumura, I; Nozaki, Y; Oribe, M; Tomita, D | 1 |
| Bai, Z; Jin, M; Li, X; Liu, R; Lu, Z; Tang, Y; Wang, G; Ye, X | 1 |
| Amuro, H; Ebina, K; Etani, Y; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kotani, T; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okada, S; Okita, Y; Onishi, A; Shiba, H; Son, Y; Yamamoto, K; Yamamoto, W | 1 |
| Ge, W; Shu, Q; Wang, M; Yang, N; Zhang, H; Zhang, T; Zhu, H | 1 |
| Chen, Y; He, J; Huang, H; Lin, J; Luo, J; Yang, Q; Yuan, F; Zhang, X | 1 |
| He, J; Luo, J; Ye, P; Yuan, F | 1 |
| Che, Q; Chen, J; Kou, Y; Li, M; Rong, X; Shu, Q; Zhang, X | 1 |
| Chen, H; Deng, Y; He, Q; Long, Z; Ren, X; Xiang, W; Yang, K; Zeng, L | 1 |
| Jingzhou, Z; Xin, KQ; Xiong, Z | 1 |
| Ikeuchi, S; Ishiguro, N; Ishii, M; Shibata, K; Yoshimura, A | 1 |
| Bi, L; Li, B; Li, P | 1 |
| Le, Y; Li, C; Liu, X; Ma, Z; Qi, S; Sun, L; Tao, C; Wang, J; Zhang, J; Zhao, J | 1 |
| Cao, H; Chen, W; Ke, Y; Lin, J; Olsen, N; Sun, C; Wang, X; Xu, B; Xu, D; Xu, G; Xu, L; Yu, Y; Yue, L | 1 |
| Gao, H; Jiang, H; Wang, M; Wang, Q; Wu, B | 1 |
| Shrestha, S; Yang, C; Zhang, J; Zhao, J | 2 |
| Hattori, K; Hattori, Y; Hirano, Y; Ishiguro, N; Kanayama, Y; Kato, T; Kojima, T; Takahashi, N | 1 |
| Kodera, H; Mizutani, S; Nanki, T; Sato, Y; Yasuoka, H; Yoshida, S | 1 |
| Aoyagi, T; Baba, H; Kanamori, H; Niitsuma-Sugaya, I; Oshima, K; Sato, Y; Seike, I; Takei, K; Tokuda, K | 1 |
| Jian, LL; Li, CH; Liu, XY; Ma, ZZ; Sun, L; Wang, XY; Yao, ZQ; Zhao, JX | 1 |
| Chen, LJ; Li, JY; Tian, F; Wen, ZH; Zhou, YJ | 1 |
| Ebina, K; Etani, Y; Goshima, A; Hirao, M; Kanamoto, T; Miura, T; Miyama, A; Nakata, K; Okamura, G; Oyama, S; Takami, K; Yoshikawa, H | 1 |
| Hata, K; Kotani, T; Matsuda, S; Matsumura, Y; Takeuchi, T; Yoshikawa, A | 1 |
| Dai, X; Fang, X; Jin, L; Li, M; Li, X; Tao, J; Wang, Y; Xia, Y | 1 |
| Hu, CJ; Jiang, N; Tian, XP; Wang, Q; Zeng, XF; Zhang, L; Zhao, JL; Zhou, S | 1 |
| Ikeuchi, S; Ishii, M; Shibata, K; Yoshimura, A | 1 |
| Cai, XN; Lu, L; Ma, H; Shao, SQ; Shu, P; Yin, HQ; Yin, SL; Zhou, DM | 1 |
| Fujimoto-Hirakawa, Y; Fukuda, W; Iwai, T; Kobayashi, T; Kuriyama, K; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagata, H; Nishikawa, R; Ohshiro, M; Shimura, Y; Tsukamoto, T; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Bi, L; Li, P; Ma, C; Wang, X; Zhao, F | 1 |
| Fujiki, Y; Kimura, Y; Kotani, T; Makino, S; Matsumura, Y; Takeuchi, T; Tokai, N; Yoshida, S; Yoshikawa, A | 1 |
| Deng, W; Miao, C; Zhang, X | 1 |
| Guo, C; Wu, R; Zheng, N | 1 |
| Cai, X; Dai, L; Guo, JP; Li, C; Li, X; Li, Y; Li, Z; Liu, D; Luo, L; Mu, R; Sun, E; Tao, Y; Wang, Y; Wei, W; Wu, L; Wu, M; Xiao, W; Ye, H; Zhang, M; Zhao, J; Zou, Y | 1 |
| Atsumi, T; Fujii, T; Harigai, M; Ikeuchi, S; Koike, T; Kushimoto, S; Kuwana, M; Matsuno, H; Mimori, T; Momohara, S; Takasaki, Y; Takei, S; Tamura, N; Yamamoto, K | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Mese, T; Ohara, S | 1 |
| Ishikawa, J; Ishikawa, K | 1 |
| Ayabe, K; Chikuda, H; Kaneko, T; Okamura, K; Sakane, H; Suto, T; Takeuchi, K; Tamura, Y; Yonemoto, Y | 1 |
| Arawaka, S; Fujiki, Y; Kimura, Y; Kotani, T; Makino, S; Matsumura, Y; Takeuchi, T; Tokai, N; Yoshida, S; Yoshikawa, A | 1 |
| Bao, C; Du, F; Fu, Q; Guo, Q; Hao, P; Liu, M; Liu, Y; Tang, L; Yan, Q; Ye, Y; Zhang, X | 1 |
| Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q | 1 |
| Hara, M; Ishiguro, N; Katayama, K; Kondo, M; Mimori, T; Nagai, K; Soen, S; Sumida, T; Yamaguchi, T; Yamamoto, K | 2 |
| Chen, S; Li, J; Liang, Y; Lu, Y; Mao, H; Shi, G; Yang, N | 1 |
| Ikari, K; Inoue, E; Ishida, O; Koenuma, N; Koyama, T; Momohara, S; Ochi, K; Sakuma, Y; Taniguchi, A; Yamanaka, H; Yano, K; Yoshida, S | 1 |
| Kobayashi, T; Okamura, K; Okura, C; Takagishi, K; Yonemoto, Y | 1 |
| Okamura, K; Okura, C; Suto, T; Takagishi, K; Yonemoto, Y | 1 |
| Hara, M; Tanaka, K; Yamaguchi, T | 1 |
| Duan, XW; Mao, SY; Shang, JJ; Shi, XD; Zhang, XL | 1 |
| Asai, N; Asai, S; Funahashi, K; Hirano, Y; Ishiguro, N; Ito, T; Kanayama, Y; Kanda, H; Kaneko, A; Kato, T; Kojima, T; Saito, K; Takagi, H; Takahashi, N; Takemoto, T; Terabe, K; Yoshioka, Y | 1 |
| Hua, M; Sun, X; Tan, W; Wang, F; Wei, Y; Zhang, M | 1 |
| Hou, N; Li, X; Liu, H; Lyu, J; Song, L; Xia, Z | 1 |
| Chen, G; Cheng, W; He, D; Liu, H; Miao, Y; Niu, X; Song, J; Wang, F; Xi, Y; Xu, Y; Yang, F; Zhu, Q | 1 |
| Feng, X; Gan, K; Tan, W; Wang, F; Xu, L; Yang, L; Zhang, M; Zhang, Q | 1 |
| Arita, Y; Kobayashi, M; Ohsone, Y; Okano, Y; Taguchi, H; Tono, T | 1 |
| Ito, S | 1 |
| Bi, LQ; Ding, R; Li, P; Wang, XT; Xu, TS; Zhang, X | 1 |
| Atsumi, T; Fujii, T; Harigai, M; Ikeuchi, S; Koike, T; Kushimoto, S; Kuwana, M; Matsuno, H; Mimori, T; Momohara, S; Takasaki, Y; Takei, S; Tamura, N | 1 |
| Mucke, HA | 1 |
| Abe, T; Hara, M; Hashimoto, H; Hoshi, K; Irimajiri, S; Matsui, N; Mizushima, Y; Nakano, S; Nobunaga, M; Sugawara, S; Yoshino, S | 1 |
| Abe, T; Hara, M; Hashimoto, H; Hoshi, K; Irimajiri, S; Matsui, N; Mizushima, Y; Nobunaga, M; Sugawara, S; Yoshino, S | 1 |
| Bao, CD; Chen, ZW; Dai, M; Du, F; Fan, W; Gu, JR; Han, XH; He, PG; Li, JH; Li, XF; Lu, LJ; Tao, Y; Teng, JL; Wu, HX; Xu, JH; Yang, NP; Yu, H; Zhang, MJ; Zhao, YH | 1 |
| Bao, CD; Du, F; Lü, LJ; Shen, N; Teng, JL; Ye, P | 1 |
| Aikawa, Y; Kizawa, K; Matsuno, H; Muraguchi, A; Muramoto, K; Tanaka, K; Yamamoto, T | 1 |
| Kawabata, D; Mimori, T | 1 |
| Hara, M | 1 |
| Bao, CD; Han, XH; Li, XF; Lü, LJ; Sun, LY; Teng, JL; Wu, HX; Xu, JH | 1 |
| Aikawa, Y; Makino, S; Matsumoto, Y; Shin, T; Tanaka, K; Tanuma, N | 1 |
12 review(s) available for iguratimod and Rheumatoid Arthritis
| Article | Year |
|---|---|
Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cytokines; Humans; Sjogren's Syndrome | 2023 |
Molecular mechanisms and clinical application of Iguratimod: A review.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Humans; Sulfonamides | 2020 |
Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Chromones; Humans; Methotrexate; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2020 |
Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis : A systematic review and meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2021 |
Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Sulfonamides | 2021 |
Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Sulfonamides | 2021 |
Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chromones; Humans; Immunosuppressive Agents; Odds Ratio; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2013 |
Iguratimod for the treatment of rheumatoid arthritis in Japan.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Japan; Methotrexate; Sulfonamides | 2015 |
[DMARDs (Focusing on iguratimod)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cysteine; Drug Discovery; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Ribonucleosides; Sulfasalazine; Sulfonamides; Tacrolimus | 2016 |
Iguratimod: a new disease-modifying antirheumatic drug.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Sulfasalazine; Sulfonamides | 2012 |
[Disease modifying anti-rheumatic drugs (DMARDs): an overview].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Cysteine; Evidence-Based Medicine; Gold Sodium Thiomalate; Humans; Isoxazoles; Leflunomide; Meta-Analysis as Topic; Methotrexate; Randomized Controlled Trials as Topic; Sulfasalazine; Sulfonamides | 2005 |
[T-614 for therapy of rheumatoid arthritis].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Cytokines; Depression, Chemical; Disease Models, Animal; Humans; Immunoglobulins; Sulfonamides | 2005 |
14 trial(s) available for iguratimod and Rheumatoid Arthritis
| Article | Year |
|---|---|
Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Gene Expression; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; RNA, Long Noncoding; Sulfonamides; Tumor Necrosis Factor-alpha | 2021 |
Effectiveness of drug safety measures for reducing the incidence of adverse drug reactions: Post-hoc analysis of data from all-case surveillance of iguratimod using generalized estimating equations.
Topics: Arthritis, Rheumatoid; Chromones; Humans; Incidence; Japan; Male; Middle Aged; Models, Biological; Product Surveillance, Postmarketing; Prospective Studies; Sulfonamides | 2021 |
Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Female; Humans; Male; Middle Aged; NF-kappa B; RANK Ligand; Sulfonamides | 2019 |
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Retreatment; Sulfonamides; Treatment Outcome | 2014 |
Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Chromones; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; China; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Sulfonamides; Treatment Outcome | 2015 |
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Attitude of Health Personnel; China; Chromones; Dose-Response Relationship, Drug; Drug Combinations; Evidence-Based Medicine; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Patient Satisfaction; Prevalence; Risk Factors; Sulfonamides; Treatment Outcome | 2016 |
Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis.
Topics: Adult; Arthritis, Rheumatoid; Chromones; Cytokines; Female; Humans; Middle Aged; Sulfonamides; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells | 2015 |
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Sulfonamides; Treatment Outcome | 2013 |
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Severity of Illness Index; Sulfasalazine; Sulfonamides | 2007 |
Long-term safety study of iguratimod in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cytokines; Female; Humans; Immunosuppressive Agents; Liver; Male; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2007 |
Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; China; Double-Blind Method; Female; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Methotrexate; Middle Aged; Sulfonamides; Treatment Outcome | 2009 |
T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Benzopyrans; Cell Migration Assays; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibroblasts; Humans; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Middle Aged; Real-Time Polymerase Chain Reaction; Sulfonamides; Synovial Membrane | 2012 |
Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Double-Blind Method; Female; Humans; Male; Middle Aged; Sulfonamides | 2008 |
43 other study(ies) available for iguratimod and Rheumatoid Arthritis
| Article | Year |
|---|---|
The effects of iguratimod combined with methotrexate and hydroxychloroquine on bone mineral density in patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone Density; Chromones; Drug Therapy, Combination; Humans; Hydroxychloroquine; Methotrexate; Retrospective Studies; Sulfonamides | 2021 |
Iguratimod versus salazosulfapyridine in rheumatoid arthritis patients with an inadequate response to methotrexate: Adjusted with propensity score matching.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Propensity Score; Retrospective Studies; Sulfasalazine; Treatment Outcome | 2023 |
Iguratimod Restrains Circulating Follicular Helper T Cell Function by Inhibiting Glucose Metabolism
Topics: Arthritis, Rheumatoid; Chromones; Glucose; Humans; Sulfonamides; T Follicular Helper Cells; T-Lymphocytes, Helper-Inducer | 2022 |
Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Retrospective Studies; Sulfonamides; Treatment Outcome | 2023 |
Serum proteomics analysis of biomarkers for evaluating clinical response to MTX/IGU therapy in early rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biomarkers; Blood Proteins; Drug Therapy, Combination; Humans; Methotrexate; Proteomics; Treatment Outcome | 2023 |
Iguratimod efficacy in palindromic rheumatism treatment.
Topics: Adjuvants, Immunologic; Arthritis, Rheumatoid; Chromones; Humans | 2023 |
Effects of iguratimod in the treatment of palindromic rheumatism: Case report.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Pain | 2023 |
A novel drug combination of Tofacitinib and Iguratimod alleviates rheumatoid arthritis and secondary osteoporosis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Combinations; Humans; Osteoporosis; Rats; Tumor Necrosis Factor-alpha; X-Ray Microtomography | 2023 |
Combination therapy of methotrexate and iguratimod for female patients with moderate to severe active rheumatoid arthritis and its impact on ovarian function.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Methotrexate; Treatment Outcome | 2023 |
Investigation of the predictors of the response to Iguratimod therapy: A
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Product Surveillance, Postmarketing; Sulfonamides | 2020 |
Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.
Topics: Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Cells, Cultured; Chromones; Citrulline; Cytokines; Female; Humans; Male; Middle Aged; Neutrophils; Peptides, Cyclic; Protein-Arginine Deiminase Type 2; Protein-Arginine Deiminase Type 4; Protein-Arginine Deiminases; Sulfonamides | 2020 |
In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Proliferation; Chromones; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Female; Humans; Hyaluronic Acid; Hydrogels; Micelles; Nanostructures; Polyvinyl Alcohol; Rats, Inbred Lew; Sulfonamides; Synoviocytes | 2019 |
Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes.
Topics: Antirheumatic Agents; Apoptosis; Arthritis, Rheumatoid; Cell Movement; Cell Proliferation; Chemokine CCL2; Chromones; Female; Fibroblasts; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; p38 Mitogen-Activated Protein Kinases; Primary Cell Culture; Signal Transduction; Sulfonamides; Synovectomy; Synovial Membrane; Synoviocytes; Tumor Necrosis Factor-alpha | 2019 |
Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Male; Middle Aged; Retrospective Studies; Sulfonamides; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2021 |
Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Betacoronavirus; Chromones; Coronavirus Infections; COVID-19; Female; Humans; Pandemics; Pneumonia, Viral; Pregnenediones; Real-Time Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Sulfonamides; Thorax; Virus Shedding | 2020 |
Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Differentiation; Cells, Cultured; Chromones; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; p38 Mitogen-Activated Protein Kinases; RANK Ligand; Rats, Wistar; Signal Transduction; Sulfonamides; Tumor Necrosis Factor-alpha | 2021 |
Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro.
Topics: Alkaline Phosphatase; Animals; Arthritis, Rheumatoid; Bone and Bones; Bone Marrow Cells; Bone Resorption; Calcification, Physiologic; Cell Count; Cell Line; Chromones; Dexamethasone; Down-Regulation; Glucocorticoids; Male; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Sulfonamides; Up-Regulation | 2021 |
The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Humans; Methotrexate; Remission Induction; Sulfonamides; Treatment Outcome | 2022 |
Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus.
Topics: Animals; Antibodies, Antinuclear; Arthritis, Rheumatoid; Chromones; Cytokines; Disease Models, Animal; Forkhead Transcription Factors; Humans; Immunoglobulins; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred BALB C; Proteinuria; Sulfonamides; T-Lymphocytes, Regulatory; Terpenes; Th17 Cells | 2021 |
Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Respiratory Function Tests; Sulfonamides; Tomography, X-Ray Computed; Young Adult | 2021 |
Iguratimod triggers the relapse of methotrexate-associated lymphoproliferative disorder.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Female; Humans; Immunosuppressive Agents; Lymphoproliferative Disorders; Methotrexate; Recurrence; Sulfonamides | 2021 |
Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Bone and Bones; Bone Remodeling; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Sulfonamides | 2017 |
Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chromones; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Remission Induction; Retrospective Studies; Sulfonamides | 2018 |
Abrupt generalized pustules in patients with rheumatoid arthritis and interstitial lung disease.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Arthritis, Rheumatoid; Biopsy; Chromones; Cyclosporine; Diagnosis, Differential; Exanthema; Female; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Paeonia; Plant Extracts; Prednisone; Psoriasis; Skin; Sulfonamides | 2018 |
Iguratimod is effective in refractory rheumatoid arthritis patients with inadequate response to methotrexate-cyclosporin A-hydroxychloroquine-prednisone.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cyclosporine; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroquine; Male; Methotrexate; Middle Aged; Prednisone; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; China; Chromones; DNA; Female; Genetic Carrier Screening; Genotype; Heterozygote; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Risk Assessment; Sulfonamides | 2018 |
Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sulfonamides; Time; Treatment Outcome | 2019 |
Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis: A Very Rare Case.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoproliferative Disorders; Male; Methotrexate; Neoplasm Recurrence, Local; Rare Diseases; Rituximab; Sulfonamides; Treatment Outcome | 2018 |
The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Sulfonamides | 2019 |
Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Female; Genetic Association Studies; Humans; Male; Matrix Metalloproteinase 3; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2018 |
Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; B-Lymphocytes; Cell Differentiation; Cells, Cultured; Chromones; Early Growth Response Protein 1; Humans; Protein Kinase C; Sulfonamides | 2019 |
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Chromones; Collagen; I-kappa B Kinase; Inflammation; Interleukin-17; Isoxazoles; Leflunomide; Male; Methotrexate; Mice; Mice, Inbred DBA; Phosphorylation; Signal Transduction; Sulfonamides; Synovial Membrane; TNF Receptor-Associated Factor 5 | 2013 |
Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cohort Studies; Databases, Factual; Female; Humans; Japan; Joints; Male; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Tacrolimus | 2014 |
Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Female; Humans; Male; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2015 |
Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Chromones; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Registries; Remission Induction; Retrospective Studies; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2016 |
Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Cells, Cultured; Chromones; Cytokines; Down-Regulation; Female; Fibroblasts; Humans; Interleukin-17; Interleukin-6; Male; Matrix Metalloproteinase 3; RANK Ligand; Sulfonamides; Synovial Membrane; Treatment Outcome | 2015 |
Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Resorption; Cell Differentiation; Cell Movement; Chromones; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Proto-Oncogene Proteins c-fos; RANK Ligand; RAW 264.7 Cells; Signal Transduction; Sulfonamides | 2016 |
Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Drug Therapy, Combination; Etanercept; Female; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Long Term Adverse Effects; Methotrexate; Pneumocystis carinii; Pneumonia, Pneumocystis; Sulfonamides | 2018 |
Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Blotting, Western; Chromones; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Humans; Interleukin-1beta; Male; Methotrexate; Middle Aged; Osteoprotegerin; RANK Ligand; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Synoviocytes | 2016 |
Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Chromones; Drug Monitoring; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Risk Factors; Sulfonamides; Treatment Outcome | 2017 |
Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; B-Lymphocytes; Benzopyrans; Cell Division; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Immunoglobulin M; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Sulfonamides; Synovial Membrane | 2003 |
A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Encephalomyelitis, Autoimmune, Experimental; Interferon-gamma; Interleukin-1; Interleukin-6; Macrophages; Microglia; Myelin Basic Protein; Rats; Rats, Inbred Lew; Spinal Cord; Sulfonamides; T-Lymphocytes; Tumor Necrosis Factor-alpha | 1998 |